EXOZ · Exozymes Inc.
$5.82
-0.18 (-3.00%)
At close · Aug 14
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Given the Company's current operating cash burn, its existing working capital as of June 30, 2026, is not sufficient to fund operations for twelve months from the date these condensed unaudited consolidated financial statements are issued, and management has concluded that substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$54.02M
Shares
9.28M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.82
Open$5.89
Day$5.82–6.49
52W close$4.40–16.50
Avg vol 30d8K
Short int22K · 0.2% float · 2.6d
Short vol9%
DataNov 2024–Aug 2026
Filing10-Q · Aug 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−41%
below
Price vs 50-day avg
−12%
below
RSI (14)
51
neutral
MACD trend
Positive
52-week position
12%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−3%
trailing
6-month return
−35%
trailing
YTD return
−47%
this year
Relative strength
−48%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
+43% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.24% of float · ▲ +11.8% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
10 holders — near 1-yr high, broad support
Squeeze score
40
low risk · 0–100
Fundamentals
EPS growth
−22%
Y/Y
Free cash flow
$-6.7M
Balance sheet
$3.0M
net cash
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−73%
past year
ATR
9.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−41%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
51
Neutral
MACD trend
Positive
Bullish
52-week position
12%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
+43% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.24% of float · ▲ +11.8% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
10 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $6 · 12%
Range high $17
vs 200-day avg -41%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EXOZ
this stock
Exozymes Inc.
|
$54.02M | -46.6% | — | — | 0.2% |
|
ONC
BeOne Medicines Ltd.
|
$530.72B | +14.4% | +22179.2% | 816.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.25B | +11.6% | +46.2% | 30.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.16B | +4.1% | +20.8% | 19.8 | 3.3% |
|
ARGX
Argenx SE
|
$52.69B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EXOZ | +14.0% | -3.3% | -34.6% | +25.2% | -46.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +13.6% | -7.8% | -48.4% | +21.2% | -60.5% |